CPT1A and hepatocellular carcinoma: In support of this view, combination of antiangiogenic drug with a β-oxidation inhibitor such as the CPT1 inhibitor etomoxir produced greater anticancer effects in an animal model of hepatocellular cancer grown in liver [30].